[작성자:] cms3billion
-
2024 희귀질환 진단 보고서: 검사 비용과 한계 및 환자에게 필요한 것
의료 기술의 빠른 변화 속에서 희귀질환 진단은 새로운 전환점을 맞이하고 있습니다. 희귀질환 환자들의 유전자 검사를 통한 진단을 제공하는 쓰리빌리언에서 처음 발간하는 ‘2024 희귀질환 진단 보고서’는 전세계 30개국의 의사들의 목소리로 환자와 의료진에게 중요한 통찰을 제공합니다. 2024년 진단의 최전선에서는 어떤 변화가 있었을까요? 1. 전장 엑솜 시퀀싱(WES): 유전자 분석, 이제는 첫 번째 선택 조사 결과, 70.8%의 의사가 희귀질환…
-
2024 Rare Disease Diagnostics Report: Cost,Challenges and Patient Needs
Rare diseases impact millions of lives worldwide, yet the journey to diagnosis remains a significant challenge for patients and healthcare systems alike. The 2024 Rare Disease Diagnostics Report sheds light on critical trends, barriers, and breakthroughs that are shaping the future of rare disease testing. This comprehensive report offers actionable insights for healthcare providers, researchers,…
-
3billion Partners with Korea Rare Disease Foundation to Enhance Genetic Testing and Counseling Services for Rare Diseases
3billion has entered a strategic collaboration with the Korea Rare Disease Foundation to enhance genetic diagnosis and counseling services for patients with developmental disabilities, autism spectrum disorders, and their families. This partnership aims to improve the quality of medical decisions and enhance patients’ and families’ quality of life through accurate genetic analysis and comprehensive communication…